United Therapeutics Corp at Cowen Health Care Conference Transcript
Good afternoon. Why don't we get started. My name is Chris Shibutani. I'm a member of the Cowen Biotech Equity Research team. We're very excited to have United Therapeutics join us once again. I think when you think about the whole scope of the companies in the biotech space, the term franchise really aptly applies to them. This is a company that really was a pioneer that created so many dimensions of this space. The entire portfolio cascades through meeting all the needs of patients.
The story continues to play out with investors kind of doing a tug-of-war over what to believe and what to be skeptical of, but nonetheless, I think what you're seeing is stock performance has actually been very resilient, and there's many opportunities ahead with additional pipeline readout that will continue to tell the story. We welcome James Edgemond, the CFO, to update us on United Therapeutics. Thanks for joining us.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |